Humacyte, Inc. Common Stock
Here’s whether Humacyte, Inc. Common Stock (HUMA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 43 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-11.57% over 10 days); weak 1-year return of -67.8%; 3-month momentum negative (-35.0%); rising volume on a downtrend (distribution, 1.32x avg). Currently 76.3% off its 52-week high. Score: -5/7.
HUMA is trading below its 200-day MA ($1.00) — a key warning sign the longer-term trend is under pressure. An RSI of 43.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -67.8% compares to +20.4% for SPY (trailed the market by 88.2%). The current 76.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.